Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Florence Schleich, MD, PhD
Advertisement
Florence Schleich, MD, PhD, a respiratory physician at the University of Liège in Belgium.
Articles by Florence Schleich, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD
3
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
4
5 Gastroenterology Headlines You Missed in September 2026
5